Quercetin improves bone strength in experimental biliary cirrhosis

Hepatology Research

Volumn 43, Issue 4, 2013, Pages 394-400

  Derakhshanian, Hoda ^a   Ghadbeigi, Sajad ^a   Rezaian, Maryam ^c   Bahremand, Arash ^b   Javanbakht, Mohammad Hassan ^a   Golpaie, Atefeh ^a   Hosseinzadeh, Payam ^a   Tajik, Narges ^a   Dehpour, Ahmad Reza ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c UNIVERSITY OF TEHRAN   (Iran)

Author keywords

Bone; Cirrhosis; Quercetin; Rat

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; OSTEOCALCIN; PHOSPHORUS; QUERCETIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE DUCT LIGATION; BILIARY CIRRHOSIS; BILIRUBIN BLOOD LEVEL; BIOMECHANICS; BONE STRENGTH; BONE TURNOVER; CONTROLLED STUDY; CORTICAL BONE; DRUG EFFECT; FEMUR; MALE; MORPHOMETRICS; NONHUMAN; OSSIFICATION; PRIORITY JOURNAL; RAT; TRABECULAR BONE;

EID: 84876098364     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2012.01075.x     Document Type: Article

References (39)

1. Solaymani-Dodaran M, Card TR, Aithal GP, West J. Fracture risk in people with primary biliary cirrhosis: a population-based cohort study. Gastroenterology 2006; 131: 1752-7.
2. Guanabens N, Pares A, Marinoso L etal. Factors influencing the development of metabolic bone disease in primary biliary cirrhosis. Am J Gastroenterol 1990; 85: 1356-62.
3. Guañabens N, Parés A, Ros I etal. Severity of cholestasis and advanced histological stage but not menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis. J Hepatol 2005; 42: 573-7.
4. Menon K, Angulo P, Weston S, Dickson ER, Lindor KD. Bone disease in primary biliary cirrhosis: independent indicators and rate of progression. J Hepatol 2001; 35: 316-23.
5. Gallego-Rojo FJ, Gonzalez-Calvin JL, Muñoz-Torres M, Mundi JL, Fernandez-Perez R, Rodrigo-Moreno D. Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis. Hepatology 1998; 28: 695-9.
6. Diamond T, Stiel D, Lunzer M, McDowall D, Eckstein R, Posen S. Hepatic osteodystrophy. Static and dynamic bone histomorphometry and serum bone Gla-protein in 80 patients with chronic liver disease. Gastroenterology 1989; 96: 213-21.
7. Hodgson S, Dickson ER, Eastell R, Eriksen E, Bryant S, Riggs B. Rates of cancellous bone remodeling and turnover in osteopenia associated with primary biliary cirrhosis. Bone 1993; 14: 819-27.
8. Zein CO, Jorgensen RA, Clarke B etal. Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial. Hepatology 2005; 42: 762-71.
9. Boone RH, Cheung AM, Girlan LM, Heathcote EJ. Osteoporosis in primary biliary cirrhosis: a randomized trial of the efficacy and feasibility of estrogen/progestin. Dig Dis Sci 2006; 51: 1103-12.
10. Dresner-Pollak R, Gabet Y, Steimatzky A etal. Human parathyroid hormone 1-34 prevents bone loss in experimental biliary cirrhosis in rats. Gastroenterology 2008; 134: 259-67.
11. Tanaka S, Tsurukami H, Sakai A etal. Effects of 1, 25 (OH) 2 D3 on turnover, mineralization, and strength of bone in growing rats with liver cirrhosis induced by administration of carbon tetrachloride. Bone 2003; 32: 275-83.
12. Wattel A, Kamel S, Prouillet C etal. Flavonoid quercetin decreases osteoclastic differentiation induced by RANKL via a mechanism involving NFκB and AP-1. J Cell Biochem 2004; 92: 285-95.
13. Wattel A, Kamel S, Mentaverri R etal. Potent inhibitory effect of naturally occurring flavonoids quercetin and kaempferol on in vitro osteoclastic bone resorption. Biochem Pharmacol 2003; 65: 35-42.
14. Wong R, Rabie A. Effect of quercetin on preosteoblasts and bone defects. Open Orthop J 2008; 10: 27-32.
15. Prouillet C, Maziere JC, Mazière C, Wattel A, Brazier M, Kamel S. Stimulatory effect of naturally occurring flavonols quercetin and kaempferol on alkaline phosphatase activity in MG-63 human osteoblasts through ERK and estrogen receptor pathway. Biochem Pharmacol 2004; 67: 1307-13.
16. Tsuji M, Yamamoto H, Sato T etal. Dietary quercetin inhibits bone loss without effect on the uterus in ovariectomized mice. J Bone Miner Metab 2009; 27: 673-81.
17. Ackerman Z, Weinreb M, Amir G, Pollak RD. Bone mineral metabolism and histomorphometry in rats with cholestatic liver disease. Liver 2002; 22: 166-72.
18. Fallon M, Abrams G, McGrath J, Hou Z, Luo B. Common bile duct ligation in the rat: a model of intrapulmonary vasodilatation and hepatopulmonary syndrome. Am J Physiol 1997; 272: G779-84.
19. Eileen HJ. Bone disease in cholestatic liver disease. Gastroenterology 1995; 108: 276-83.
20. Rouillard S, Lane NE. Hepatic osteodystrophy. Hepatology 2001; 33: 301-7.
21. Nakano A, Kanda T, Abe H. Liver and bone. J Gastroenterol Hepatol 1996; 11: 1143-54.
22. Van der Merwe S, Van den Bogaerde J, Goosen C etal. Hepatic osteodystrophy in rats results mainly from portasystemic shunting. Gut 2003; 52: 580-5.
23. Janes C, Dickson ER, Okazaki R, Bonde S, McDonagh A, Riggs B. Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice. J Clin Invest 1995; 95: 2581-6.
24. Wong RWK, Rabie ABM. Effect of quercetin on bone formation. J Orthop Res 2008; 26: 1061-6.
25. Kountouras J, Billing B, Scheuer P. Prolonged bile duct obstruction: a new experimental model for cirrhosis in the rat. Br J Exp Pathol 1984; 65: 305-11.
26. Shin MO, Moon JO. Effect of dietary supplementation of grape skin and seeds on liver fibrosis induced by dimethylnitrosamine in rats. Nutr Res Pract 2010; 4: 369-74.
27. Tieppo J, Cuevas MJ, Vercelino R, Tuñón MJ, Marroni NP, González-Gallego J. Quercetin administration ameliorates pulmonary complications of cirrhosis in rats. J Nutr 2009; 139: 1339-46.
28. Batta A. Comparative study of serum 5′nucleotidase, alkaline phosphatase, aminotransferases and bilirubin in hepatpbilrary diseases. Int J Cur Biomed Phar Res 2011; 1: 93-7.
29. Duarte MP, Farias MLF, Coelho HSM etal. Calcium-parathyroid hormone-vitamin D axis and metabolic bone disease in chronic viral liver disease. J Gastroenterol Hepatol 2001; 16: 1022-7.
30. Cemborain A, Castilla-Cortázar I, García M etal. Osteopenia in rats with liver cirrhosis: beneficial effects of IGF-I treatment. J Hepatol 1998; 28: 122-31.
31. Cassidy A. Potential risks and benefits of phytoestrogen-rich diets. Int J Vitam Nutr Res 2003; 73: 120-6.
32. Chen YM, Ho SC, Lam SSH, Ho SSS, Woo JLF. Soy isoflavones have a favorable effect on bone loss in Chinese postmenopausal women with lower bone mass: a double-blind, randomized, controlled trial. J Clin Endocrinol Metab 2003; 88: 4740-7.
33. Wattel A, Kamel S, Prouillet C etal. Flavonoid quercetin decreases osteoclastic differentiation induced by RANKL via a mechanism involving NF B and AP 1. J Cell Biochem 2004; 92: 285-95.
34. Kim DS, Takai H, Arai M etal. Effects of quercetin and quercetin 3-glucuronide on the expression of bone sialoprotein gene. J Cell Biochem 2007; 101: 790-800.
35. Ruiz-Gaspà S, Martinez-Ferrer A, Guañabens N etal. Effects of bilirubin and sera from jaundiced patients on osteoblasts: contribution to the development of osteoporosis in liver diseases. Hepatology 2011; 54: 2104-13.
36. Chen CC, Wang SS, Jeng FS, Lee SD. Metabolic bone disease of liver cirrhosis: is it parallel to the clinical severity of cirrhosis? J Gastroenterol Hepatol 1996; 11: 417-21.
37. Yang Y, Yang Z, Wang D, Xiao X, Li P. Comparative study on effects of rutin and quercetin on metabolism in osteoblast cells. Zhong Yao Cai 2006; 29: 467-70.
38. Son YO, Kook SH, Choi KC etal. Quercetin accelerates TNF-[alpha]-induced apoptosis of MC3T3-E1 osteoblastic cells through caspase-dependent and JNK-mediated pathways. Eur J Pharmacol 2008; 579: 26-33.
39. Woo JT, Nakagawa H, Notoya M etal. Quercetin suppresses bone resorption by inhibiting the differentiation and activation of osteoclasts. Biol Pharm Bull 2004; 27: 504-9.